{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:51:32Z","timestamp":1770339092518,"version":"3.49.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1A3B3079653"],"award-info":[{"award-number":["NRF-2020R1A3B3079653"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017R1A2A1A17069780"],"award-info":[{"award-number":["NRF-2017R1A2A1A17069780"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HR14C0003"],"award-info":[{"award-number":["HR14C0003"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Therapy-related myeloid neoplasm (T-MN) rarely occurs among cancer survivors, and was\u00a0characterized by poor prognosis. T-MN has germline predisposition in a considerable proportion. Here, clinical characteristics and germline\/somatic variant profiles in T-MN patients were investigated, and the findings were compared with those of previous studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A review of medical records, cytogenetic study, targeted sequencing by next-generation sequencing, and survival analysis were performed on 53 patients with T-MN at a single institution in Korea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The patients were relatively younger compared to T-MN patients in other studies. Our T-MN patients showed a\u00a0high frequency of complex karyotypes, \u22125\/del(5q), and \u22127\/del(7q), which was similar to the Japanese study group but higher than the Australian study group. The most common primary disease was non-Hodgkin lymphoma, followed by breast cancer. The detailed distributions of primary diseases were different across study groups. Seven patients (13.2%) harbored deleterious presumed\/potential germline variants in cancer predisposition genes (CPG) such as<jats:italic>BRIP1<\/jats:italic>,<jats:italic>CEBPA<\/jats:italic>,<jats:italic>DDX41<\/jats:italic>,<jats:italic>FANCM<\/jats:italic>,<jats:italic>NBN<\/jats:italic>,<jats:italic>NF1<\/jats:italic>, and<jats:italic>RUNX1<\/jats:italic>. In the somatic variant profile,<jats:italic>TP53<\/jats:italic>was the most frequently mutated gene, which was consistent with the previous studies about T-MN. However, the somatic variant frequency in our study group was lower than in other studies. Adverse factors for overall survival were male sex, older age, history of previous radiotherapy, previous longer cytotoxic therapy, and \u22125\/del(5q).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The findings of our study corroborate important information about T-MN patients. As well as a considerable predisposition to CPG, the clinical characteristics and somatic variant profile showed distinctive patterns. Germline variant testing should be recommended for T-MN patients. If the T-MN patients harbor pathogenic germline variants, the family members for stem cell donation should be screened for carrier status through germline variant testing to avoid donor-derived myeloid neoplasm. For the prediction of the prognosis in T-MN patients, sex, age, past treatment history, and cytogenetic findings can be considered.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40246-023-00458-8","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T03:03:36Z","timestamp":1677121416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea"],"prefix":"10.1186","volume":"17","author":[{"given":"Jiwon","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyojin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soonok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Ryun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dajeong","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunghoon","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongseok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Soon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"458_CR1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017.","edition":"4"},{"issue":"10","key":"458_CR2","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/ajh.21828","volume":"85","author":"AJ De Roos","year":"2010","unstructured":"De Roos AJ, Deeg HJ, Onstad L, Kopecky KJ, Bowles EJ, Yong M, et al. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005\u20132006. Am J Hematol. 2010;85(10):765\u201370.","journal-title":"Am J Hematol"},{"issue":"3","key":"458_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.23908","volume":"90","author":"E Huleg\u00e5rdh","year":"2015","unstructured":"Huleg\u00e5rdh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf \u00c5, et al. Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry. Am J Hematol. 2015;90(3):208\u201314.","journal-title":"Am J Hematol"},{"key":"458_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.leukres.2018.07.013","volume":"71","author":"GS Guru Murthy","year":"2018","unstructured":"Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E. Incidence and survival of therapy related myeloid neoplasm in United States. Leuk Res. 2018;71:95\u20139.","journal-title":"Leuk Res"},{"issue":"9","key":"458_CR5","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME McNerney","year":"2017","unstructured":"McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17(9):513\u201327.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"458_CR6","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cncr.29615","volume":"122","author":"JE Churpek","year":"2016","unstructured":"Churpek JE, Marquez R, Neistadt B, Claussen K, Lee MK, Churpek MM, et al. Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer. 2016;122(2):304\u201311.","journal-title":"Cancer"},{"issue":"7","key":"458_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/jmedgenet-2011-100674","volume":"49","author":"E Schulz","year":"2012","unstructured":"Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V, et al. Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. J Med Genet. 2012;49(7):422\u20138.","journal-title":"J Med Genet"},{"issue":"7","key":"458_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.44","volume":"5","author":"MT Voso","year":"2015","unstructured":"Voso MT, Fabiani E, Zang Z, Fianchi L, Falconi G, Padella A, et al. Fanconi anemia gene variants in therapy-related myeloid neoplasms. Blood Cancer J. 2015;5(7): e323.","journal-title":"Blood Cancer J"},{"issue":"6","key":"458_CR9","first-page":"795","volume":"7","author":"PG Cachia","year":"1993","unstructured":"Cachia PG, Culligan DJ, Clark RE, Whittaker JA, Jacobs A, Padua RA. Clonal haemopoiesis following cytotoxic therapy for lymphoma. Leukemia. 1993;7(6):795\u2013800.","journal-title":"Leukemia"},{"issue":"7432","key":"458_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11725","volume":"493","author":"E Ruark","year":"2013","unstructured":"Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, et al. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493(7432):406\u201310.","journal-title":"Nature"},{"issue":"3","key":"458_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamaoncol.2015.6053","volume":"2","author":"EM Swisher","year":"2016","unstructured":"Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, et al. Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma. JAMA Oncol. 2016;2(3):370\u20132.","journal-title":"JAMA Oncol"},{"issue":"3","key":"458_CR12","doi-asserted-by":"publisher","first-page":"djv347","DOI":"10.1093\/jnci\/djv347","volume":"108","author":"PDP Pharoah","year":"2016","unstructured":"Pharoah PDP, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, et al. ppm1d mosaic truncating variants in ovarian cancer cases may be treatment-related somatic mutations. J Natl Cancer Inst. 2016;108(3):djv347.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"458_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","volume":"18","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18(1):100\u201311.","journal-title":"Lancet Oncol"},{"issue":"1","key":"458_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12185-011-1001-x","volume":"95","author":"MH Raaijmakers","year":"2012","unstructured":"Raaijmakers MH. Myelodysplastic syndromes: revisiting the role of the bone marrow microenvironment in disease pathogenesis. Int J Hematol. 2012;95(1):17\u201325.","journal-title":"Int J Hematol"},{"key":"458_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/bs.acr.2015.04.007","volume":"127","author":"P Agarwal","year":"2015","unstructured":"Agarwal P, Bhatia R. Influence of bone marrow microenvironment on leukemic stem cells: breaking up an intimate relationship. Adv Cancer Res. 2015;127:227\u201352.","journal-title":"Adv Cancer Res"},{"issue":"1","key":"458_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.it.2013.10.002","volume":"35","author":"BA Anthony","year":"2014","unstructured":"Anthony BA, Link DC. Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol. 2014;35(1):32\u20137.","journal-title":"Trends Immunol"},{"issue":"7","key":"458_CR17","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1182\/blood-2016-09-670224","volume":"129","author":"C Korn","year":"2017","unstructured":"Korn C, M\u00e9ndez-Ferrer S. Myeloid malignancies and the microenvironment. Blood. 2017;129(7):811\u201322.","journal-title":"Blood"},{"issue":"7540","key":"458_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518(7540):552\u20135.","journal-title":"Nature"},{"issue":"12","key":"458_CR19","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1038\/s41375-019-0479-8","volume":"33","author":"D Singhal","year":"2019","unstructured":"Singhal D, Wee LYA, Kutyna MM, Chhetri R, Geoghegan J, Schreiber AW, et al. The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Leukemia. 2019;33(12):2842\u201353.","journal-title":"Leukemia"},{"key":"458_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.cancergen.2018.02.006","volume":"222\u2013223","author":"T Nishiyama","year":"2018","unstructured":"Nishiyama T, Ishikawa Y, Kawashima N, Akashi A, Adachi Y, Hattori H, et al. Mutation analysis of therapy-related myeloid neoplasms. Cancer Genet. 2018;222\u2013223:38\u201345.","journal-title":"Cancer Genet"},{"issue":"1","key":"458_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ajhg.2018.04.013","volume":"103","author":"J Whitworth","year":"2018","unstructured":"Whitworth J, Smith PS, Martin J-E, West H, Luchetti A, Rodger F, et al. Comprehensive cancer-predisposition gene testing in an adult multiple primary tumor series shows a broad range of deleterious variants and atypical tumor phenotypes. Am J Hum Genet. 2018;103(1):3\u201318.","journal-title":"Am J Hum Genet"},{"issue":"7483","key":"458_CR22","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature12981","volume":"505","author":"N Rahman","year":"2014","unstructured":"Rahman N. Realizing the promise of cancer predisposition genes. Nature. 2014;505(7483):302\u20138.","journal-title":"Nature"},{"issue":"9","key":"458_CR23","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1200\/JCO.2016.70.8644","volume":"35","author":"E Furutani","year":"2017","unstructured":"Furutani E, Shimamura A. Germline genetic predisposition to hematologic malignancy. J Clin Oncol. 2017;35(9):1018\u201328.","journal-title":"J Clin Oncol"},{"issue":"24","key":"458_CR24","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336\u201346.","journal-title":"N Engl J Med"},{"key":"458_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00258","volume":"3","author":"Z Akras","year":"2019","unstructured":"Akras Z, Bungo B, Leach BH, Marquard J, Ahluwalia M, Carraway H, et al. Primer on hereditary cancer predisposition genes included within somatic next-generation sequencing panels. JCO Precis Oncol. 2019;3:1\u201311.","journal-title":"JCO Precis Oncol"},{"key":"458_CR26","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice guidelines in Oncology (NCCN Guidelines\u00ae) Acute Myeloid Leukemia (Version 3.2021, updated March 2, 2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf. Accessed 6 Apr 2021."},{"key":"458_CR27","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice guidelines in Oncology (NCCN Guidelines\u00ae) Myelodysplastic Syndromes (Version 3.2021, updated January 15, 2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf. Accessed 6 Apr 2021."},{"issue":"14","key":"458_CR28","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/bioinformatics\/bts280","volume":"28","author":"H Li","year":"2012","unstructured":"Li H. Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly. Bioinformatics. 2012;28(14):1838\u201344.","journal-title":"Bioinformatics"},{"key":"458_CR29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, Del Angel G, Levy-Moonshine A, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinform. 2013;43:11.","journal-title":"Curr Protoc Bioinform"},{"issue":"22","key":"458_CR30","doi-asserted-by":"publisher","first-page":"11189","DOI":"10.1093\/nar\/gks918","volume":"40","author":"A Wilm","year":"2012","unstructured":"Wilm A, Aw PP, Bertrand D, Yeo GH, Ong SH, Wong CH, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res. 2012;40(22):11189\u2013201.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"458_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani P, Platts A, le Wang L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6(2):80\u201392.","journal-title":"Fly (Austin)"},{"issue":"D1","key":"458_CR32","doi-asserted-by":"publisher","first-page":"D733","DOI":"10.1093\/nar\/gkv1189","volume":"44","author":"NA O'Leary","year":"2016","unstructured":"O\u2019Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: current status, taxonomic expansion, and functional annotation. Nucleic Acids Res. 2016;44(D1):D733\u201345.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"458_CR33","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019;47(D1):D941\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"458_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST Sherry","year":"2001","unstructured":"Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308\u201311.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"458_CR35","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"7616","key":"458_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285\u201391.","journal-title":"Nature"},{"issue":"10","key":"458_CR37","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00439-020-02199-3","volume":"139","author":"PD Stenson","year":"2020","unstructured":"Stenson PD, Mort M, Ball EV, Chapman M, Evans K, Azevedo L, et al. The human gene mutation database (HGMD((R))): optimizing its use in a clinical diagnostic or research setting. Hum Genet. 2020;139(10):1197\u2013207.","journal-title":"Hum Genet"},{"issue":"1","key":"458_CR38","doi-asserted-by":"publisher","first-page":"14297","DOI":"10.1038\/s41598-020-71386-z","volume":"10","author":"B Kim","year":"2020","unstructured":"Kim B, Yun W, Lee ST, Choi JR, Yoo KH, Koo HH, et al. Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia. Sci Rep. 2020;10(1):14297.","journal-title":"Sci Rep"},{"issue":"5","key":"458_CR39","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201323.","journal-title":"Genet Med"},{"issue":"11","key":"458_CR40","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/humu.23626","volume":"39","author":"AN Abou Tayoun","year":"2018","unstructured":"Abou Tayoun AN, Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, et al. Recommendations for interpreting the loss of function PVS1 ACMG\/AMP variant criterion. Hum Mutat. 2018;39(11):1517\u201324.","journal-title":"Hum Mutat"},{"issue":"1","key":"458_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn. 2017;19(1):4\u201323.","journal-title":"J Mol Diagn"},{"issue":"3","key":"458_CR42","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","volume":"176","author":"K Jaganathan","year":"2019","unstructured":"Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176(3):535-48.e24.","journal-title":"Cell"},{"issue":"7728","key":"458_CR43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526\u201331.","journal-title":"Nature"},{"issue":"23","key":"458_CR44","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"22","key":"458_CR45","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616\u201327.","journal-title":"Blood"},{"issue":"1","key":"458_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-016-0287-9","volume":"9","author":"SM Hwang","year":"2016","unstructured":"Hwang SM, Kim SY, Kim JA, Park H-S, Park SN, Im K, et al. Short telomere length and its correlation with gene mutations in myelodysplastic syndrome. J Hematol Oncol. 2016;9(1):62.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"458_CR47","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cancergencyto.2006.02.015","volume":"168","author":"SM Bang","year":"2006","unstructured":"Bang SM, Kim YR, Cho HI, Chi HS, Seo EJ, Park CJ, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet. 2006;168(2):124\u201332.","journal-title":"Cancer Genet Cytogenet"},{"issue":"12","key":"458_CR48","doi-asserted-by":"publisher","first-page":"e0167641","DOI":"10.1371\/journal.pone.0167641","volume":"11","author":"J-A Kim","year":"2016","unstructured":"Kim J-A, Hwang B, Park SN, Huh S, Im K, Choi S, et al. Genomic profile of chronic lymphocytic leukemia in Korea identified by targeted sequencing. PLoS ONE. 2016;11(12):e0167641.","journal-title":"PLoS ONE"},{"issue":"6","key":"458_CR49","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00412-010-0285-6","volume":"119","author":"F Zhang","year":"2010","unstructured":"Zhang F, Fan Q, Ren K, Auerbach AD, Andreassen PR. FANCJ\/BRIP1 recruitment and regulation of FANCD2 in DNA damage responses. Chromosoma. 2010;119(6):637\u201349.","journal-title":"Chromosoma"},{"issue":"3","key":"458_CR50","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2020.257246","volume":"107","author":"JT Weinreb","year":"2022","unstructured":"Weinreb JT, Gupta V, Sharvit E, Weil R, Bowman TV. Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish. Haematologica. 2022;107(3):644\u201354.","journal-title":"Haematologica"},{"issue":"1","key":"458_CR51","doi-asserted-by":"publisher","first-page":"7314","DOI":"10.1038\/s41467-021-27530-y","volume":"12","author":"T Mosler","year":"2021","unstructured":"Mosler T, Conte F, Longo GMC, Mikicic I, Kreim N, M\u00f6ckel MM, et al. R-loop proximity proteomics identifies a role of DDX41 in transcription-associated genomic instability. Nat Commun. 2021;12(1):7314.","journal-title":"Nat Commun"},{"issue":"12","key":"458_CR52","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.dnarep.2011.09.006","volume":"10","author":"M Huang","year":"2011","unstructured":"Huang M, Kennedy R, Ali AM, Moreau LA, Meetei AR, D\u2019Andrea AD, et al. Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. DNA Repair. 2011;10(12):1203\u201312.","journal-title":"DNA Repair"},{"issue":"1","key":"458_CR53","doi-asserted-by":"publisher","first-page":"19110","DOI":"10.1038\/s41598-019-55537-5","volume":"9","author":"X Pan","year":"2019","unstructured":"Pan X, Chen Y, Biju B, Ahmed N, Kong J, Goldenberg M, et al. FANCM suppresses DNA replication stress at ALT telomeres by disrupting TERRA R-loops. Sci Rep. 2019;9(1):19110.","journal-title":"Sci Rep"},{"issue":"2","key":"458_CR54","first-page":"99","volume":"43","author":"AS Samarakkody","year":"2020","unstructured":"Samarakkody AS, Shin NY, Cantor AB. Role of RUNX family transcription factors in DNA damage response. Mol Cells. 2020;43(2):99\u2013106.","journal-title":"Mol Cells"},{"issue":"2","key":"458_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1074\/jbc.M112.402594","volume":"288","author":"D Wu","year":"2013","unstructured":"Wu D, Ozaki T, Yoshihara Y, Kubo N, Nakagawara A. Runt-related transcription factor 1 (RUNX1) stimulates tumor suppressor p53 protein in response to DNA damage through complex formation and acetylation. J Biol Chem. 2013;288(2):1353\u201364.","journal-title":"J Biol Chem"},{"issue":"3","key":"458_CR56","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/humu.23955","volume":"41","author":"A Fi\u00e9vet","year":"2020","unstructured":"Fi\u00e9vet A, Bellanger D, Zahed L, Burglen L, Derrien AC, Dubois d\u2019Enghien C, et al. DNA repair functional analyses of NBN hypomorphic variants associated with NBN-related infertility. Hum Mutat. 2020;41(3):608\u201318.","journal-title":"Hum Mutat"},{"issue":"2","key":"458_CR57","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1074\/jbc.M706734200","volume":"283","author":"JF Haince","year":"2008","unstructured":"Haince JF, McDonald D, Rodrigue A, D\u00e9ry U, Masson JY, Hendzel MJ, et al. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem. 2008;283(2):1197\u2013208.","journal-title":"J Biol Chem"},{"issue":"3","key":"458_CR58","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/85820","volume":"27","author":"T Pabst","year":"2001","unstructured":"Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT\/enhancer binding protein-alpha (C\/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27(3):263\u201370.","journal-title":"Nat Genet"},{"issue":"2","key":"458_CR59","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/ng0296-144","volume":"12","author":"G Bollag","year":"1996","unstructured":"Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet. 1996;12(2):144\u20138.","journal-title":"Nat Genet"},{"issue":"7","key":"458_CR60","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1438::AID-CNCR22>3.0.CO;2-#","volume":"79","author":"JM Maris","year":"1997","unstructured":"Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CG, et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer. 1997;79(7):1438\u201346.","journal-title":"Cancer"},{"issue":"2","key":"458_CR61","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"KL Huang","year":"2018","unstructured":"Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173(2):355-70.e14.","journal-title":"Cell"},{"key":"458_CR62","doi-asserted-by":"publisher","first-page":"10086","DOI":"10.1038\/ncomms10086","volume":"6","author":"C Lu","year":"2015","unstructured":"Lu C, Xie M, Wendl MC, Wang J, McLellan MD, Leiserson MD, et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015;6:10086.","journal-title":"Nat Commun"},{"issue":"10","key":"458_CR63","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1038\/s41375-018-0049-5","volume":"32","author":"U Wartiovaara-Kautto","year":"2018","unstructured":"Wartiovaara-Kautto U, Hirvonen EAM, Pitk\u00e4nen E, Heckman C, Saarela J, Kettunen K, et al. Germline alterations in a consecutive series of acute myeloid leukemia. Leukemia. 2018;32(10):2282\u20135.","journal-title":"Leukemia"},{"issue":"2","key":"458_CR64","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/bloodadvances.2017013037","volume":"2","author":"MW Drazer","year":"2018","unstructured":"Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, et al. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018;2(2):146\u201350.","journal-title":"Blood Adv"},{"issue":"3","key":"458_CR65","doi-asserted-by":"publisher","first-page":"e0212228","DOI":"10.1371\/journal.pone.0212228","volume":"14","author":"B Kim","year":"2019","unstructured":"Kim B, Lee H, Jang J, Kim SJ, Lee ST, Cheong JW, et al. Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasms. PLoS ONE. 2019;14(3):e0212228.","journal-title":"PLoS ONE"},{"issue":"6","key":"458_CR66","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1097\/HS9.0000000000000321","volume":"3","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Tesi B, Wartiovaara-Kautto U, Stray-Pedersen A, Friis LS, Dybedal I, et al. Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up. Hemasphere. 2019;3(6):e321.","journal-title":"Hemasphere"},{"issue":"1","key":"458_CR67","doi-asserted-by":"publisher","first-page":"40","DOI":"10.47429\/lmo.2021.11.1.40","volume":"11","author":"S-H Mun","year":"2021","unstructured":"Mun S-H, Suh HS, Jeon C-H, Lee AJ, Yoo E-H, Kim S-G. Next-generation sequencing myeloid panel test for patients with AML and MDS: experience in a tertiary care hospital. Lab Med Online. 2021;11(1):40\u20136.","journal-title":"Lab Med Online"},{"issue":"5","key":"458_CR68","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.stem.2018.10.004","volume":"23","author":"JI Hsu","year":"2018","unstructured":"Hsu JI, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F, et al. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell. 2018;23(5):700-13.e6.","journal-title":"Cell Stem Cell"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-023-00458-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-023-00458-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-023-00458-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T13:25:29Z","timestamp":1701955529000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-023-00458-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["458"],"URL":"https:\/\/doi.org\/10.1186\/s40246-023-00458-8","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"assertion":[{"value":"8 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Declaration of Helsinki. All BM samples were collected with informed consent, and the study was reviewed and approved by the Institutional Review Board of Seoul National University College of Medicine (IRB No. 2001-139-1096).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no potential competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}